|Prof. Lindy Gillian Durrant Ph.D.||Founder, CEO, Chief Scientific Officer & Director||376.88k||N/A||N/A|
|Dr. Sally Elizabeth Adams||Chief Devel. Officer & Director||255.65k||N/A||1961|
|Mr. Keith Green||Director of Fin. & Admin. and Company Sec.||N/A||N/A||N/A|
|Dr. Samantha Paston Ph.D.||Head of Translational Research||N/A||N/A||N/A|
|Dr. Adrian Parry Ph.D.||Head of Manufacturing||N/A||N/A||N/A|
|Ms. Akua Asare||Head of Quality||N/A||N/A||N/A|
|Mr. Fayaz Master||Head of Clinical Operations||N/A||N/A||N/A|
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
Scancell Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.